Datasheet

Mouse mAb to MFG-E8/

Lactadherin/p47.

Clone MFG-06 Isotype IgG1- κ




Source

A BALB/c mouse was immunized with a milk fat globule membrane preparation derived from human breast cancer cell line PMC42. Fusion partner: P3-X63-Ag8.653.

Specifications

MFG-06 reacts with a glycoprotein of 40-45 kDa, known as Milk fat globule-EGF factor 8 protein (MFG-E8), lactadherin, p47 or milk fat globule 1 antigen. It is present on normal epithelial cells in various organs and considered a differentiation marker in carcinomas. It contains one EGF-like domain and 2 F5/8 type C domains. Functioning as a specific ligand for Integrin $\beta 5$ and Integrin $\beta 3$, MFG-E8 is thought to be involved in gamete interactions and cell attachment, possibly playing a role in fertilization and apoptosis. Additionally, MFG-E8 binds to rotavirus and inhibits its replication, thereby protecting the cell from viral infection.






Figure 1: Human kidney stained with MFG-06 (paraffin)

Species reactivity

Positive: human, rat.

Applications

Classification of carcinomas. Distinguish embryonal carcinomas from seminomas.

Flow cytometry	Frozen sections	Immunofluorescence	Paraffin sections	Western blot
+	+	+	Citrate	+

Format

Produced in tissue culture, contains no host Ig. Antibodies are affinity purified and presented in PBS with 0,02 % sodium azide.

Stored at 4°C-8°C, shelf life is at least 24 months after purchase.

Dilution advice

- Flow cytometry $(0.5-1.0 \mu g/million cells in 0.1 ml)$.
- \triangleright Immunoblotting (1-2 µg/ml).
- \triangleright Immunofluorescence (0,5-1,0 µg/ml).
- \triangleright Immunohistology (1-2 μg/ml for 30 min at RT; staining of formalin-fixed tissues requires boiling tissue sections in 10mM citrate buffer, pH 6.0, for 10-20 min followed by cooling at RT for 20 minutes).




Figure 2: Human breast cancer stained with MFG-06 (paraffin)

Positive control

Normal breast or breast carcinoma.

Datasheet



References

- > Bártková J, et. al. *Tumour Biol.* **8(1):** 45-56 (1987).
- Yamazaki, M. et al. *Lab. Invest.* **94**: 1260-72 (2014).
- Alfaro-Lira, S. et al. 2012. *Int J Environ Res Public Health.* **9**: 1630-1648 (2012).